Enhancing recombinant mRNA translation via interactions with the 3-UTR for improved recombinant protein yields
通过与 3-UTR 相互作用增强重组 mRNA 翻译,从而提高重组蛋白产量
基本信息
- 批准号:BB/F018053/1
- 负责人:
- 金额:$ 9.24万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Training Grant
- 财政年份:2008
- 资助国家:英国
- 起止时间:2008 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
A recently discovered addition to translational control is the existence of small (~22nt) non-coding microRNAs (miRNAs). These RNAs repress translation of mRNAs that have target binding sites in their 3' untranslated region (3'UTRs). Multiple miRNAs can act on a single gene, however one miRNA may act on many different genes, leading to complex combinatorial regulatory networks. Cap-dependent translation may be promoted by mRNA 'looping' mediated by interaction of the poly-A tail with the cap. In current models of miRNA function, mature miRNA complexed in micro-ribonucleoprotein particles bind to their cognate sequence in the 3'UTR of mRNA and interfere with this interaction, leading to translational repression. Under certain conditions, miRNA may also promote mRNA degradation. MicroRNAs are critical for cell proliferation, death and differentiation; all of these features are important parameters for the selection of high-producing cell lines that grow well in suspension culture. Very little information exists about the function of miRNAs in recombinant cell lines, including CHO cells, used for manufacturing therapeutic proteins. To our knowledge, only the induction of growth inhibitory miRNAs mIR-21 and -24 by temperature shift or during normal batch culture have been reported in CHO cells. At Lonza we recently undertook an extensive miRNA profiling study using the miRCURY LNA microarray and found that ~56 miRNA are significantly differentially expressed during the course of a state-of-the-art industrial fed-batch bioreactor culture. On the basis of the available data, we propose the following hypothesis: Over or under-expressed miRNA in antibody-producing cell lines are functional and are not just a phenotypic feature of host cell lines in general. We plan to demonstrate that miRNAs have a role in controlling the productivity of an antibody-producing CHOK1SV cell line and begin elucidating the mechanism(s) by which these work. We propose initially to investigate a subset of the 56 miRNA that we have already identified as being differentially expressed during fermentation of CHO cells. We will concentrate upon the 5 most up/down-regulated miRNAs (which we will confirm by qRT-PCR) to determine their effect on cell growth and recombinant gene expression. We will use commercially available anti-miRNA inhibitors and follow the effect on antibody and reporter gene (luciferase) expression in stable CHO cell lines. We will also determine the effect on antibody heavy/light chain and luciferase polypeptide synthetic rates (that reflect mRNA translation) in control cells and those transiently transfected with miRNA inhibitors by immunoprecipitation followed by SDS-PAGE/phosphorimaging. To detect changes in heavy/light chain and luciferase mRNA turnover we will use actinomycin D and qRT-PCR to calculate the half-life of these transcripts in the presence and absence of miRNA inhibitors. To confirm that any changes/improvements are due to knockdown of miRNAs we will use commercially available miRNA precursor molecules (Ambion) to up-regulate the expression of the specific miRNAs of interest. The effects on antibody mRNA translational rates will be determined as described above. To begin investigating the mechanism by which miRNAs may effect recombinant protein synthesis, we will use 35S-Met labelling of nascent polypeptide chains and 2D analysis/phosphorimaging to investigate the global effect on polypeptide synthesis. For those protein spots that are up/down-regulated in response to miRNA over-expression or knockdown, we will identify the protein by mass spectrometry and use qRT-PCR to confirm that the miRNA of interest does change the mRNA turnover and/or levels that code for the identified protein. The 3'-UTR will then be cloned into a luciferase reporter gene construct and transiently transfected into CHO cells. The effect upon reporter gene expression +/- the appropriate miRNA will be determine
最近发现的除了翻译控制之外的是小(~ 22 nt)非编码microRNA(miRNAs)的存在。这些RNA抑制在其3'非翻译区(3' UTR)中具有靶结合位点的mRNA的翻译。多个miRNA可以作用于单个基因,然而一个miRNA可以作用于许多不同的基因,导致复杂的组合调控网络。帽依赖性翻译可通过多聚腺苷酸尾与帽的相互作用介导的mRNA“成环”来促进。在目前的miRNA功能模型中,复合在微小核糖核蛋白颗粒中的成熟miRNA与mRNA的3 'UTR中的同源序列结合并干扰这种相互作用,导致翻译抑制。在某些条件下,miRNA也可促进mRNA降解。microRNA对细胞增殖、死亡和分化至关重要;所有这些特征都是选择在悬浮培养中生长良好的高产细胞系的重要参数。关于miRNA在用于制造治疗性蛋白质的重组细胞系(包括CHO细胞)中的功能的信息非常少。据我们所知,在CHO细胞中仅报道了通过温度变化或在正常分批培养期间诱导生长抑制性miRNAs mIR-21和-24。在Lonza,我们最近使用miRCURY LNA微阵列进行了一项广泛的miRNA谱研究,发现在最先进的工业补料分批生物反应器培养过程中,约56种miRNA显著差异表达。在现有数据的基础上,我们提出了以下假设:在抗体产生细胞系中过表达或低表达的miRNA是功能性的,而不仅仅是宿主细胞系的表型特征。我们计划证明miRNAs在控制产生抗体的CHOK 1 SV细胞系的生产力中具有作用,并开始阐明这些工作的机制。我们建议首先研究我们已经确定为在CHO细胞发酵过程中差异表达的56种miRNA的一个子集。我们将集中于5个上调/下调最多的miRNAs(我们将通过qRT-PCR确认),以确定它们对细胞生长和重组基因表达的影响。我们将使用市售的抗miRNA抑制剂,并在稳定的CHO细胞系中跟踪对抗体和报告基因(荧光素酶)表达的影响。我们还将通过免疫沉淀法和随后的SDS-PAGE/磷光成像法确定对照细胞和用miRNA抑制剂瞬时转染的细胞中抗体重链/轻链和荧光素酶多肽合成速率(反映mRNA翻译)的影响。为了检测重/轻链和荧光素酶mRNA周转的变化,我们将使用放线菌素D和qRT-PCR来计算这些转录物在存在和不存在miRNA抑制剂的情况下的半衰期。为了证实任何变化/改善是由于miRNA的敲低,我们将使用市售的miRNA前体分子(Ambion)来上调感兴趣的特定miRNA的表达。将如上所述测定对抗体mRNA翻译速率的影响。为了开始研究miRNA影响重组蛋白合成的机制,我们将使用新生多肽链的35 S-Met标记和2D分析/磷光成像来研究对多肽合成的整体影响。对于那些响应于miRNA过表达或敲低而上调/下调的蛋白质点,我们将通过质谱法鉴定蛋白质,并使用qRT-PCR来确认感兴趣的miRNA确实改变了编码所鉴定蛋白质的mRNA周转和/或水平。然后将3 '-UTR克隆到荧光素酶报告基因构建体中并瞬时转染到CHO细胞中。将确定对报告基因表达+/-适当的miRNA的影响
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
其他文献
吉治仁志 他: "トランスジェニックマウスによるTIMP-1の線維化促進機序"最新医学. 55. 1781-1787 (2000)
Hitoshi Yoshiji 等:“转基因小鼠中 TIMP-1 的促纤维化机制”现代医学 55. 1781-1787 (2000)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
LiDAR Implementations for Autonomous Vehicle Applications
- DOI:
- 发表时间:
2021 - 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
吉治仁志 他: "イラスト医学&サイエンスシリーズ血管の分子医学"羊土社(渋谷正史編). 125 (2000)
Hitoshi Yoshiji 等人:“血管医学与科学系列分子医学图解”Yodosha(涉谷正志编辑)125(2000)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Effect of manidipine hydrochloride,a calcium antagonist,on isoproterenol-induced left ventricular hypertrophy: "Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,K.,Teragaki,M.,Iwao,H.and Yoshikawa,J." Jpn Circ J. 62(1). 47-52 (1998)
钙拮抗剂盐酸马尼地平对异丙肾上腺素引起的左心室肥厚的影响:“Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('', 18)}}的其他基金
An implantable biosensor microsystem for real-time measurement of circulating biomarkers
用于实时测量循环生物标志物的植入式生物传感器微系统
- 批准号:
2901954 - 财政年份:2028
- 资助金额:
$ 9.24万 - 项目类别:
Studentship
Exploiting the polysaccharide breakdown capacity of the human gut microbiome to develop environmentally sustainable dishwashing solutions
利用人类肠道微生物群的多糖分解能力来开发环境可持续的洗碗解决方案
- 批准号:
2896097 - 财政年份:2027
- 资助金额:
$ 9.24万 - 项目类别:
Studentship
A Robot that Swims Through Granular Materials
可以在颗粒材料中游动的机器人
- 批准号:
2780268 - 财政年份:2027
- 资助金额:
$ 9.24万 - 项目类别:
Studentship
Likelihood and impact of severe space weather events on the resilience of nuclear power and safeguards monitoring.
严重空间天气事件对核电和保障监督的恢复力的可能性和影响。
- 批准号:
2908918 - 财政年份:2027
- 资助金额:
$ 9.24万 - 项目类别:
Studentship
Proton, alpha and gamma irradiation assisted stress corrosion cracking: understanding the fuel-stainless steel interface
质子、α 和 γ 辐照辅助应力腐蚀开裂:了解燃料-不锈钢界面
- 批准号:
2908693 - 财政年份:2027
- 资助金额:
$ 9.24万 - 项目类别:
Studentship
Field Assisted Sintering of Nuclear Fuel Simulants
核燃料模拟物的现场辅助烧结
- 批准号:
2908917 - 财政年份:2027
- 资助金额:
$ 9.24万 - 项目类别:
Studentship
Assessment of new fatigue capable titanium alloys for aerospace applications
评估用于航空航天应用的新型抗疲劳钛合金
- 批准号:
2879438 - 财政年份:2027
- 资助金额:
$ 9.24万 - 项目类别:
Studentship
Developing a 3D printed skin model using a Dextran - Collagen hydrogel to analyse the cellular and epigenetic effects of interleukin-17 inhibitors in
使用右旋糖酐-胶原蛋白水凝胶开发 3D 打印皮肤模型,以分析白细胞介素 17 抑制剂的细胞和表观遗传效应
- 批准号:
2890513 - 财政年份:2027
- 资助金额:
$ 9.24万 - 项目类别:
Studentship
CDT year 1 so TBC in Oct 2024
CDT 第 1 年,预计 2024 年 10 月
- 批准号:
2879865 - 财政年份:2027
- 资助金额:
$ 9.24万 - 项目类别:
Studentship
Understanding the interplay between the gut microbiome, behavior and urbanisation in wild birds
了解野生鸟类肠道微生物组、行为和城市化之间的相互作用
- 批准号:
2876993 - 财政年份:2027
- 资助金额:
$ 9.24万 - 项目类别:
Studentship
相似海外基金
Develop and Assess mRNA Lipid Nanoparticle Vaccines Against Cryptococcosis
开发并评估针对隐球菌病的 mRNA 脂质纳米颗粒疫苗
- 批准号:
10616313 - 财政年份:2023
- 资助金额:
$ 9.24万 - 项目类别:
Mineral Coated Microparticles for Stabilization and Delivery of Complexed mRNA for Healing of Long Bone Defects
用于稳定和递送复合 mRNA 的矿物涂层微粒,用于治疗长骨缺损
- 批准号:
10464358 - 财政年份:2023
- 资助金额:
$ 9.24万 - 项目类别:
Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs
基于 mRNA 的自我扩增疫苗可引发 VRC01 级 bnAb
- 批准号:
10589641 - 财政年份:2023
- 资助金额:
$ 9.24万 - 项目类别:
Oral mRNA Nanotherapy for Bleeding Disorder
口服 mRNA 纳米疗法治疗出血性疾病
- 批准号:
10750040 - 财政年份:2023
- 资助金额:
$ 9.24万 - 项目类别:
A New Lipid Nanoparticle Technology Enabling Long-acting mRNA Therapy
新型脂质纳米颗粒技术实现长效 mRNA 治疗
- 批准号:
10669826 - 财政年份:2023
- 资助金额:
$ 9.24万 - 项目类别:
CST6-mRNA activated matrices for efficient bone regeneration
CST6-mRNA 激活基质可实现高效骨再生
- 批准号:
10576944 - 财政年份:2022
- 资助金额:
$ 9.24万 - 项目类别:
Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis
新型结核分枝杆菌 mRNA 疫苗的开发
- 批准号:
10625373 - 财政年份:2022
- 资助金额:
$ 9.24万 - 项目类别:
CST6-mRNA activated matrices for efficient bone regeneration
CST6-mRNA 激活基质可实现高效骨再生
- 批准号:
10456455 - 财政年份:2022
- 资助金额:
$ 9.24万 - 项目类别:
Development of Novel mRNA Vaccines Against Mycobacterium tuberculosis
新型结核分枝杆菌 mRNA 疫苗的开发
- 批准号:
10440618 - 财政年份:2022
- 资助金额:
$ 9.24万 - 项目类别:
Development of Programmable mRNA Circuits for Melanoma Immunotherapy
用于黑色素瘤免疫治疗的可编程 mRNA 电路的开发
- 批准号:
10258632 - 财政年份:2021
- 资助金额:
$ 9.24万 - 项目类别: